|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the ELN 6-K filed Mar 30, 2009. Review
of the Development of the Business
Elan Corporation, plc, an Irish public limited company, is a
neuroscience-based biotechnology company headquartered in
Dublin, Ireland. Our shares trade on the New York, London and
Irish Stock Exchanges and our principal R&D, manufacturing
and marketing facilities are located in Ireland and the United
States.
Our business is organised into two business units:
Biopharmaceuticals and EDT. Biopharmaceuticals engages in
research, development and commercial activities primarily in
Alzheimer’s disease, Parkinson’s disease, multiple
sclerosis, Crohn’s disease, severe chronic pain and
infectious diseases. EDT is an established, profitable specialty
pharmaceutical business unit of Elan. For nearly 40 years,
EDT has been applying its skills and knowledge to enhance the
performance of dozens of drugs that have subsequently been
marketed worldwide.
A detailed review of our performance during the financial year
is included in the “Financial Review” section of this
Annual Report.
The future success of the Biopharmaceuticals business depends on
the continued successful commercialisation of Tysabri and
the successful development and commercialisation of additional
products. The future success of the EDT business depends on our
ability to drive growth through our existing approved licensed
products and pipeline of products in clinical development, our
ability to generate new pipeline opportunities by entering into
further licensing arrangements with pharmaceutical companies,
and on our ability to identify and develop proprietary products.
Information on legal proceedings pending against Elan is
contained in Note 29 to the Consolidated Financial
Statements. For further discussion of the risk factors that
impact us, please refer to the “Risk Factors” section
of this Annual Report.
This excerpt taken from the ELN 6-K filed Mar 31, 2008. Review
of the Development of the Business
Elan Corporation, plc, an Irish public limited company, is a
neuroscience-based biotechnology company headquartered in
Dublin, Ireland. Our shares trade on the New York, London and
Irish Stock Exchanges and our principal R&D, manufacturing
and marketing facilities are located in Ireland and the United
States.
Our operations are organised into two business units:
Biopharmaceuticals and EDT. Biopharmaceuticals engages in
research, development and commercial activities primarily in
Alzheimer’s disease, Parkinson’s disease, multiple
sclerosis, Crohn’s disease, severe chronic pain and
infectious diseases. EDT is an established, profitable and
growing specialty pharmaceutical business unit of Elan. For
nearly 40 years, EDT has been applying its skills and
knowledge to enhance the performance of dozens of drugs that
have been marketed worldwide.
A detailed review of our performance during the financial year
is included in the “Financial Review” section of this
Annual Report.
The future success of the Biopharmaceuticals business depends on
the continued successful commercialisation of Tysabri and
the successful development of additional products. The future
success of the EDT business depends on our ability to drive
growth through our existing approved licensed products and
pipeline of products in clinical development, our ability to
generate new pipeline opportunities by entering into further
licensing arrangements with pharmaceutical companies, and on our
ability to identify and develop proprietary products.
Information on legal proceedings pending against Elan is
contained in Note 30 to the Consolidated Financial
Statements. For further discussion of the risk factors which
impact us, please refer to the “Risk Factors” section
of this Annual Report.
This excerpt taken from the ELN 6-K filed Mar 30, 2007. Review
of the Development of the Business
Elan Corporation, plc, an Irish public limited company, is a
neuroscience-based biotechnology company headquartered in
Dublin, Ireland. Our shares trade on the New York, London and
Irish Stock Exchanges and our principal R&D, manufacturing
and marketing facilities are located in Ireland and the United
States.
Our operations are organised into two business units:
Biopharmaceuticals and EDT. Biopharmaceuticals engages in
research, development and commercial activities and includes our
activities in the areas of autoimmune diseases,
neurodegenerative diseases, and our specialty business group.
EDT focuses on product development,
scale-up and
manufacturing to address drug optimisation challenges of the
pharmaceutical industry.
A detailed review of our performance during the financial year
is included in the “Financial Review” section of this
Annual Report.
The future success of the Biopharmaceuticals business depends on
the successful development and commercialisation of Tysabri
and the successful development of additional products. The
future success of the EDT business depends on our ability to
increase the number of third-party products that incorporate our
technologies and to increase our manufacturing activities for
third parties.
Information on legal proceedings pending against Elan is
contained in Note 31 to the Consolidated Financial
Statements. For further discussion of the risk factors which
impact us, please refer to the “Risk Factors” section
of this Annual Report.
This excerpt taken from the ELN 6-K filed Mar 31, 2006. Review of the Development of the
Business
Elan Corporation, plc, an Irish public limited company, is a
neuroscience-based biotechnology company headquartered in
Dublin, Ireland. Our shares trade on the New York, London and
Irish Stock Exchanges and our principal research and
development, manufacturing and marketing facilities are located
in Ireland, the United States and the United Kingdom.
Our business is organised into two business units:
Biopharmaceuticals and EDT. Biopharmaceuticals engages in
research, development and commercial activities and includes our
activities in the areas of autoimmune diseases,
neurodegenerative diseases, and our specialty business group.
EDT focuses on product development,
scale-up and
manufacturing to address drug optimisation challenges of the
pharmaceutical industry.
A detailed review of our performance during the financial year
is included in the “Financial Review” section of this
Annual Report.
The future success of the Biopharmaceuticals business depends on
the successful development and commercialisation of Tysabri
and the successful development of additional products. The
future success of the EDT business depends on our ability to
increase the number of third-party products that incorporate our
technologies and to increase our manufacturing activities for
third parties.
Information on legal proceedings pending against Elan is
contained in Note 30 to the Consolidated Financial
Statements. For further discussion of the risk factors which
impact us, please refer to the “Risk Factors” section
of this Annual Report.
This excerpt taken from the ELN 6-K filed Apr 11, 2005. Review of the Development of the Business We are focused on the discovery, development, manufacturing, sale and marketing of novel therapeutic products in neurodegenerative diseases, autoimmune diseases and severe pain. Our shares trade on the New York, London and Irish Stock Exchanges. Elan Corporation, plc is the parent company of a group of subsidiaries whose principal activities are described in the Operating and Financial Reviews on pages 4 to 44 of this report. Information on legal proceedings pending against Elan is contained in Note 26 to the Consolidated Financial Statements. | EXCERPTS ON THIS PAGE:
RELATED TOPICS for ELN: |
| |||||||
